Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
0(0%)
Results Posted
42%(5 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_3
5
33%
Ph phase_1
4
27%
Ph phase_2
3
20%
Ph phase_4
3
20%

Phase Distribution

4

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
4(26.7%)
Phase 2Efficacy & side effects
3(20.0%)
Phase 3Large-scale testing
5(33.3%)
Phase 4Post-market surveillance
3(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(12)
Terminated(1)
Other(2)

Detailed Status

Completed12
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (26.7%)
Phase 23 (20.0%)
Phase 35 (33.3%)
Phase 43 (20.0%)

Trials by Status

unknown213%
terminated17%
completed1280%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT02415556Phase 2

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

Completed
NCT02556918Phase 4

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

Completed
NCT02443402Phase 4

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Completed
NCT00542633Phase 3

An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus

Completed
NCT00542724Phase 3

An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

Completed
NCT00849576Phase 3

Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.

Completed
NCT01000922Phase 2

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

Completed
NCT00883558Phase 2

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Completed
NCT00862849Phase 1

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Completed
NCT01490762Phase 1

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

Completed
NCT00511979Phase 1

Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin

Completed
NCT01417897Phase 4

Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study

Unknown
NCT00668850Phase 3

Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin

Unknown
NCT00982254Phase 1

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

Completed
NCT00287066Phase 3

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

Terminated

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15